Mrs. Cathleen A. Distor, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 548 South Marine Corps Drive, Tamuning, GU 96913 Phone: 671-646-5824 Fax: 671-647-3546 |
Ms. Jeanelle Martinez, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 472 Chalan San Antonio, Pemar Place, Tamuning, GU 96913 Phone: 671-647-1830 Fax: 671-647-1919 |
Monica Webb, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 472 Chalan San Antonio, Tamuning, GU 96913 Phone: 671-647-1830 |
Mrs. Christina Joy Anciano, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 472 Chalan San Antonio, Tamuning, GU 96913 Phone: 671-300-6310 Fax: 671-647-1919 |
Kathryn May Cooper, Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 472 Chalan San Antonio, Tamuning, GU 96913 Phone: 671-300-6310 Fax: 671-647-1919 |
News Archive
Men who eat an average of half a serving of soy food a day have lower concentrations of sperm than men who do not eat soy foods, according to research published online in Europe's leading reproductive medicine journal, Human Reproduction, today (Thursday 24 July). The association was particularly marked in men who were overweight or obese, the study found.
Researchers at the University of Cambridge have managed to reconstruct the early stage of mammalian development using embryonic stem cells, showing that a critical mass of cells – not too few, but not too many – is needed for the cells to being self-organising into the correct structure for an embryo to form.
NI Research has released the March/April issue of NeuroPerspective, which features comprehensive reviews of two major areas: Schizophrenia and Spinal cord injury.
Tumors of the colon, so-called colorectal carcinomas, are the second to third most frequent tumors in women and men in Germany. The surgical removal of the tumors is a central component of the therapy.
Savient Pharmaceuticals, Inc. announced that its board of directors, with input from its financial advisors, has determined that a sale of Savient post-approval of KRYSTEXXA by the U.S. Food and Drug Administration (assuming KRYSTEXXA is approved) would be the best way to realize the full commercial potential of KRYSTEXXA on a global basis and would be the optimal outcome for the Company's shareholders and other stakeholders.
› Verified 4 days ago